$2.99
-0.41 (-12.06%)
Open$3.38
Previous Close$3.40
Day High$3.40
Day Low$2.84
52W High$48.78
52W Low$3.68
Volume—
Avg Volume14.2K
Market Cap6.31M
P/E Ratio—
EPS$-197.29
SectorBiotechnology
Analyst Ratings
Strong Buy
7 analysts
Price Target
+844.8% upside
Current
$2.99
$2.99
Target
$28.25
$28.25
$22.50
$28.25 avg
$48.31
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 1.10M | 989.8K | 1.05M |
| Net Income | -234,853 | -218,932 | -208,731 |
| Profit Margin | -21.4% | -22.1% | -19.9% |
| EBITDA | -290,262 | -298,722 | -291,498 |
| Free Cash Flow | -192,766 | -116,937 | -167,359 |
| Rev Growth | -6.5% | +19.5% | +20.8% |
| Debt/Equity | 0.95 | 1.14 | 1.06 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $249.68 | -0.45% | 118.6 | 430.95B |
| AMGN | Amgen Inc | $412.84 | -1.20% | 25.1 | 219.39B |
| GILD | Gilead Sciences Inc | $138.12 | -0.01% | — | 165.85B |
| VRTX | Vertex Pharmaceuticals Inc | $508.33 | -1.57% | 28.3 | 124.51B |
| REGN | Regeneron Pharmaceuticals | $803.64 | -0.29% | 18.4 | 79.53B |
| ALNY | Alnylam Pharmaceuticals Inc | $227.29 | +0.07% | 35.2 | 28.41B |